Remimazolam As a Sole Sedative Agent for Gastrostomy Tubes Placed in the Interventional Radiology Suite: A Case Series.
Journal
A&A practice
ISSN: 2575-3126
Titre abrégé: A A Pract
Pays: United States
ID NLM: 101714112
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
Remimazolam is an ultrashort acting intravenous sedative-hypnotic approved for procedural sedation. We report a series of 8 cases of radiographically placed gastrostomy tubes using remimazolam as the sole anesthetic agent. Interventional radiology (IR) gastrostomy tube placement entails anesthetizing often complex patients in a nonoperating room environment. All 8 patients reported here underwent successful gastrostomy tube placement without the need for conversion to general anesthesia. Remimazolam is a feasible option to sedate patients for gastrostomy tube placement in the IR suite.
Identifiants
pubmed: 39105528
doi: 10.1213/XAA.0000000000001839
pii: 02054229-202408000-00004
doi:
Substances chimiques
Hypnotics and Sedatives
0
remimazolam
7V4A8U16MB
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
e01839Informations de copyright
Copyright © 2024 International Anesthesia Research Society.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Kilpatrick GJ, McIntyre MS, Cox RF, et al. CNS 7056. Anesthesiology. 2007;107:60–66.
Zhao M, Hu H, Li X, Li X, Wang D, Kuang M. The safety and efficacy between remimazolam and propofol in intravenous anesthesia of endoscopy operation: a systematic review and meta-analysis. Int J Surg. 2023;109:3566–3577.
Pastis NJ, Yarmus LB, Schippers F, et al.; PAION Investigators. Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest. 2019;155:137–146.
Carey TS, Hanson LC, Garrett JM, et al. Expectations and outcomes of gastric feeding tubes. Am J Med. 2006;119:527.e11–527.e16.
Stöhr T, Colin PJ, Ossig J, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth. 2021;127:415–423.
Chen X, Sang N, Song K, et al. Psychomotor recovery following remimazolam-induced sedation and the effectiveness of flumazenil as an antidote. Clin Ther. 2020;42:614–624.
Lee HJ, Lee HB, Kim Y, Cho HY, Kim WH, Seo J. Comparison of the recovery profile of remimazolam with flumazenil and propofol anesthesia for open thyroidectomy. BMC Anesthesiol. 2023;23:147.
Chen S, Wang J, Xu X, et al. The efficacy and safety of remimazolam tosylate versus propofol in patients undergoing colonoscopy: a multicentered, randomized, positive-controlled, phase III clinical trial. Am J Transl Res. 2020;12:4594–4603.
Ko CC, Hung KC, Illias AM, et al. The use of remimazolam versus propofol for induction and maintenance of general anesthesia: a systematic review and meta-analysis. Front Pharmacol. 2023;14:1101728.
Jeon YG, Kim S, Park JH, et al. Incidence of intraoperative hypotension in older patients undergoing total intravenous anesthesia by remimazolam versus propofol: a randomized controlled trial. Medicine (Baltimore). 2023;102:e36440–e36440.
Kim G, Kim YY, Heo HJ, Park J. Remimazolam sedation with regional anesthesia in difficult airway due to huge thyroid goiter: a case report. Medicine (Baltimore). 2023;102:e35497–e35497.
Nagrebetsky A, Gabriel RA, Dutton RP, Urman RD. Growth of nonoperating room anesthesia care in the United States. Anesth Analg. 2017;124:1261–1267.